KD 247Alternative Names: Anti-HIV monoclonal antibody - Kaketsuken (Chemo-Sero Therapeutic Research Institute); Anti-V3 humanised antibody KD-247; KD-247
Latest Information Update: 21 Sep 2010
At a glance
- Originator Kaketsuken
- Developer Kaketsuken; Kumamoto University; University of Missouri-Columbia
- Class Antiretrovirals; Monoclonal antibodies
- Mechanism of Action HIV envelope protein gp120 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Phase I HIV-1 infections
Most Recent Events
- 21 Sep 2010 KD 247 is still in a Phase-I trial for HIV-1 infections in USA (IV)